Q3 2024
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Novo Nordisk launches initiative to tackle childhood obesity
- EU regulators recommend Wegovy® label update to include heart failure benefits
- ESSENCE trial showcases semaglutide’s potential in MASH
- Performance highlights for Q3 2024
Q2 2024
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Application for semaglutide 1 mg label extension in the US
- Expansion of US manufacturing capacity
- Results from the FRONTIER 2 clinical trial
- Tackling CO2 emissions in a time of unprecedented growth
- Performance highlights for Q2 2024
Q1 2024
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Our priorities in CVD
- Cities for Better Health
- Novo Nordisk aims to boost production capacity through acquisitions
- Performance highlights for Q1 2024
Q3 2023
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Novo Nordisk adjusts its launch and distribution strategy amid global supply constraints
- Novo Nordisk to acquire clinical candidate for uncontrolled hypertension
- New partnership to supply human insulin to millions of people across the African continent
- Novo Nordisk halts once-weekly injectable semaglutide kidney outcomes trial based on positive interim analysis
- Novo Nordisk and UNICEF extend joint initiative to prevent global childhood obesity
Q2 2023
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- SELECT results show semaglutide 2.4 mg significantly reduces major adverse cardiovascular events
- Novo Nordisk continues investments to expand production capacity
- NEW FRONTIERS: Gene-editing partnership takes aim at hard-to-treat genetic disorders
- Novo Nordisk launches world’s first cross-industry solution for recycling injection pens
- Novo Nordisk to undertake 1:2 share split
Q1 2023
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Novo Nordisk raises sales and operating profit outlook for 2023
- A century of innovation, research and dedication
- Novo Nordisk announces lower insulin pricing in the US, effective from January 2024
- Oral semaglutide 25 mg and 50 mg show promise in phase 3 trial
Q3 2022
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
- Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and other rare blood disorders
- Novo Nordisk partners with Microsoft to accelerate drug discovery and development using big data and artificial intelligence
- Saxenda® obesity sales at an all-time
high
Q2 2022
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Novo Nordisk invests in expansion of production capacity to meet growing patient demand
- A work of ‘smart’: Dialoq® launch brings digital connectivity to pre-filled insulin pens
- Driving change in diabetes, one pedal stroke at a time
- One step closer to bringing the world’s first once-weekly insulin treatment to patients
Q1 2022
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Our response to the war in Ukraine
- Taking obesity treatment to the next level
- Strengthening the pipeline in rare disease
- Harnessing the power of disruptive research technologies to develop next-generation treatments
Q3 2021
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Key milestone reached in fight to ensure no child dies from diabetes
- Production ramped up as initial demand for Wegovy in the US exceeds supply
- ASCVD: Taking aim at one of the world’s biggest killers
- Towards zero environmental impact: 15% reduction in CO2 emissions from suppliers
Q2 2021
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- New stem cell partnership targets chronic heart failure
- Ozempic® approved in China
- Novo Nordisk teams up with the University of Toronto to kickstart a new era in preventive public health
- Stepping up the game in obesity treatment: WegovyTM approved in the US
Q1 2021
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- R&D organisation evolves into two areas
- Oral semaglutide set to enter phase 3 development for Alzheimer’s disease
- Digital health: first smart pens launched in Sweden
- Rybelsus® launched in Japan – one of the world’s largest oral anti-diabetes markets
Q3 2020
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Phase 2 trial successfully completed with ziltivekimab
- Raised 2020 outlook on 8 October 2020
- Not if, but how: new strategy steps up our efforts to Defeat Diabetes
- 100% renewable power target for direct suppliers launched in 2020
- 100 years young: why we’re investing in the future of insulin
Q2 2020
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Clinical results support Strategic Aspiration for obesity treatment
- Novo Nordisk acquires Corvidia Therapeutics and expands presence in cardiovascular disease
- Lose or reuse? How we are repurposing our insulin pens
- A deep dive into NASH and Novo Nordisk’s activities in tackling this disease
- Highlights from the first six months of 2020
Q1 2020
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- An unprecedented challenge: our response to COVID-19
- Rybelsus® approved in the EU
- Obesity through the lens: the truth from within
- Prevention or cure? When it comes to type 1 diabetes, we are working on both
- Highlights from the first three months of 2020
Q3 2019
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- A new era in diabetes care: Rybelsus® approved in the USA
- New affordability initiatives to be launched in the USA
- People and purpose: Monique Carter on driving culture change at Novo Nordisk
- Intensifying China’s fight against diabetes
- Highlights from the first six months of 2019
Q2 2019
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- A new mindset for environmental responsibility
- Obesity: The brain is the battleground
- Outcomes trials: Can semaglutide go even further in addressing patient needs?
- Maximising the growth potential
- Listen and lead: Ludovic Helfgott on returning biopharm to growth
- Highlights from the first six months of 2019
Q1 2019
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Oral semaglutide filed in the US and EU
- The day I fired my doctor
- Safely in the Rainbow
- Shaped tablet key to oral delivery of insulin
- Novo Nordisk addresses affordable insulin
- Accelerating growth in Latin America
- Highlights from the first three months of 2019
Q3 2018
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first nine months of 2018
- Tresiba® revitalised with new ‘Hypos matter’
- Novo Nordisk research centre opens in oxford
- Connected insulin pens poised for launch
Q2 2018
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first six months of 2018
- Oral semaglutide shows promising results
- Ozempic® heading for the European market
- Novo Nordisk focuses on treating obesity
- Red Cross and Novo Nordisk enters partnership
Q1 2018
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first three months of 2018
- Oral semaglutide shows promising results
- Ozempic® approved in the EU and Japan
- First phase 3a trial with oral semaglutide completed
- Updated Tresiba® label approved in the USA
- How Novo Nordisk’s products in Cuba
Q3 2017
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first nine months of 2017
- Camilla Sylvest joins executive management
- SUSTAIN 7: Semaglutide compared to dulaglutide
- Victoza® CV label approved in the US and the EU
- Fiasp® a fast-acting insulin approved in the US
- Ambitious global goal: To prevent 100 million new cases of diabetes by 2045
Q2 2017
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first six months of 2017
- Label update for Tresiba® submitted in the US
- A step closer towards a CV indication for Victoza®
- Phase 2 obesity data for semaglutide
- New data on Xultophy®
- Why Novo Nordisk is helping refugees
Q1 2017
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first three months of 2017
- Doug Langa new head of North America Operations
- Fiasp® launched in Canada and EU markets
- New research centre in Oxford
- CHMP endorses Refixia®
- World Diabetes Foundation 15 th anniversary
Investors
Share price
{{priceData.date}} {{priceData.time}}